News & Events category:
COVID-19

MFT has continued its contribution to the global fight against Coronavirus by enrolling patients in a ground-breaking new study of the virus.

Our first patient has participated in the RUXCOVID research trial, which is testing whether the drug ruxolitinib could be a potential treatment for COVID-19 (coronavirus).

Our first patient has taken part in an interventional research trial testing potential treatments for people with severe COVID-19 infection, being cared for in an Intensive Care Unit.

Our first patient has taken part in the PRIEST study, a research trial aiming to optimise the triage of people using the emergency care system during the COVID-19 (coronavirus) pandemic.

Staff at MFT, already caring for patients on the frontline, are now helping fight the battle against COVID-19 by taking part in research

Our first patient has taken part in a research trial testing whether SNG001 – a drug treatment administered via a nebuliser – could be a potential treatment for COVID-19 (coronavirus).

MFT has recruited more than 400 patients to research trials in an attempt to better understand and treat COVID-19.

The first MFT patient has taken part in a research trial which is testing potential treatments for COVID-19 (coronavirus).